Posted by Michael Wonder on 25 Apr 2022
Swissmedic grants conditional marketing authorisation for Novavax COVID-19 vaccine
13 April 2022 - Nuvaxovid is the first protein-based COVID-19 vaccine authorised for use in Switzerland.
Novavax today announced that Swissmedic has granted Novavax conditional marketing authorisation for Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
